• ANURUPA OJAH Department of Pharmaceutics, Girijananda Chowdhury Institute of Pharmaceutical Science, Hatkhowapara, Azara, Guwahati-17,
  • BIPULNATH Department of Pharmaceutics, Girijananda Chowdhury Institute of Pharmaceutical Science, Hatkhowapara, Azara, Guwahati-17,
  • TRISHNA DAS Department of Pharmacognosy, Girijananda Chowdhury Institute of Pharmaceutical Science, Azara, Hatkhowapara, Guwahati-17




AIDS, HIV, Nanocarrier technology, Targeted drug delivery


AIDS is a major challenge in the 21st century. AIDS, stands for Acquired Immune Deficiency Syndrome, is a serious health problem and a fast-spreading incurable disease. It is a disorder of the cell-mediated immune system of the body. It is localized in certain inaccessible compartment of the body such as the CNS, lymphatic system and in the macrophages, where it cannot be reached by the majority of the therapeutic agent in adequate concentration or in which the therapeutic agents cannot for the necessary duration. HIV/AIDS infection are reducing incidence with the advent of Highly Active Antiretroviral Therapy (HAART). There remain a number of challenges including drug resistance, anatomical barriers to antiretroviral therapy. To overcome these different nanocarriers with the stimuli-responsive release are proposed for antiretroviral agents. Nanocarrier and those optimized for cancer chemotherapy. These include the development nanoparticles capable of passive and active targeting as well as those that are responsive to various internal and externl triggers. Nanocarriers can also provide many of the advantages of lipid system. Liposome, solid lipid nanoparticle, nanoemulsion, dendrimers, polymeric nanoparticle are the example of drug delivery systems that are under investigation for the treatment of HIV/AIDS. This review aims to summarize the ability of nanocarrier technology to provide a rational approach for anti-HIV therapy.


Download data is not yet available.


1. Vyas TK, Shah L, Mansoor MA. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opinion 2006;3:613-8.
2. Kumar L, Verma S, Prasad DP. Nanotechnology: a magic bullet for HIV AIDS treatment. Artificial Cells Nanomed Biotechnol 2015;43:71–86.
3. Parboosing R, Maguire GEM, Govender P. Nanotechnology and the treatment of HIV infection. Viruses 2012;11:488-520.
4. Bummer PM. Physical-chemical considerations of lipid-based oral drug delivery-solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst 2004;21:1-20.
5. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002;16:595-609.
6. Villalonga BC, Micha SM, Steele BR, Georgopolous A. Dendrimers as biopharmaceuticals: synthesis and properties. Curr Top Med Chem 2008;8:1294–309.
7. Shenoy D, Little S, Langer R. Poly (ethylene oxide)-modified poly (?-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. M In vivo distribution and tumor localization studies. Pharm Res 2005;22:2107-14.
8. Torchilin VP. Lipid-core micelles for targeted drug delivery. Curr Drug Delivery 2005;2:319-27.
9. Roney C, Kulkarni P, Arora V. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer’s disease. J Controlled Release 2005;108:193-214.
10. Basu MK, LALA S. Macrophage-specific drug delivery in experimental leishmaniasis. Curr Mol Med 2004;4:681-9.
11. Adhikary RR, Morea P, Banerjeea R. Smart nanoparticles as targeting platforms for HIV infections. Royal Soc Chem 2004;3:1-16.



How to Cite

OJAH, A., BIPULNATH, and T. DAS. “DIFFERENT TYPES OF NANOCARRIERS FOR TARGETED TREATMENT OF HIV/AIDS”. International Journal of Current Pharmaceutical Research, vol. 11, no. 4, July 2019, pp. 66-69, doi:10.22159/ijcpr.2019v11i4.34956.



Review Article(s)